[go: up one dir, main page]

NL300894I2 - cenegermin - Google Patents

cenegermin Download PDF

Info

Publication number
NL300894I2
NL300894I2 NL300894C NL300894C NL300894I2 NL 300894 I2 NL300894 I2 NL 300894I2 NL 300894 C NL300894 C NL 300894C NL 300894 C NL300894 C NL 300894C NL 300894 I2 NL300894 I2 NL 300894I2
Authority
NL
Netherlands
Prior art keywords
ngf
biologically active
preparation
beta
proform
Prior art date
Application number
NL300894C
Other languages
English (en)
Original Assignee
Wacker Chemie Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wacker Chemie Ag filed Critical Wacker Chemie Ag
Publication of NL300894I2 publication Critical patent/NL300894I2/nl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/48Nerve growth factor [NGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NL300894C 1998-10-09 2017-09-28 cenegermin NL300894I2 (nl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98119077A EP0994188B1 (de) 1998-10-09 1998-10-09 Verfahren zur Gewinnung von aktivem Beta-NGF

Publications (1)

Publication Number Publication Date
NL300894I2 true NL300894I2 (nl) 2018-02-01

Family

ID=8232766

Family Applications (1)

Application Number Title Priority Date Filing Date
NL300894C NL300894I2 (nl) 1998-10-09 2017-09-28 cenegermin

Country Status (14)

Country Link
US (2) US8318671B1 (nl)
EP (1) EP0994188B1 (nl)
JP (2) JP4634611B2 (nl)
KR (1) KR100593831B1 (nl)
AT (1) ATE257514T1 (nl)
AU (1) AU765810B2 (nl)
BR (1) BR9914393B1 (nl)
CA (1) CA2346257C (nl)
DE (1) DE59810555D1 (nl)
ES (1) ES2213861T3 (nl)
FR (1) FR17C0007I2 (nl)
NL (1) NL300894I2 (nl)
WO (1) WO2000022119A1 (nl)
ZA (1) ZA200102780B (nl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0994188B1 (de) 1998-10-09 2004-01-07 Scil proteins GmbH Verfahren zur Gewinnung von aktivem Beta-NGF
WO2004056385A2 (en) 2002-12-20 2004-07-08 Neuronicon Aps Modulation of activity of neurotrophins
EP3225251B1 (en) 2006-12-21 2020-02-12 H. Lundbeck A/S Modulation of activity of proneurotrophins
PT2907521T (pt) 2011-12-19 2018-02-22 Wacker Chemie Ag Mutantes prongf inovadores e utilizações dos mesmos na produção de beta-ngf
CN103880943A (zh) * 2014-01-20 2014-06-25 厦门北大之路生物工程有限公司 一种rhNGF成熟肽的制备方法
CN106519024A (zh) * 2015-09-15 2017-03-22 三生国健药业(上海)股份有限公司 一种用于去除单克隆抗体中异构体的复性液及复性方法
EP3406259A1 (en) 2017-05-24 2018-11-28 Dompé farmaceutici S.p.A. Neurotrophins for use in the treatment of hearing loss
CN108467428A (zh) * 2018-03-26 2018-08-31 江苏中新医药有限公司 一种清除rhNGF中N端截短及异常变异体的方法
WO2019207106A1 (en) 2018-04-27 2019-10-31 Chiesi Farmaceutici Spa Production of nerve growth factor (ngf) and of muteins thereof
CN113226350B (zh) 2018-09-17 2024-09-10 奇斯药制品公司 皮肤病治疗剂
CN110093394B (zh) * 2019-05-10 2023-10-03 重庆科润生物医药研发有限公司 一种蛋白包涵体及重组人β-神经生长因子的制备方法
US20220401517A1 (en) 2019-09-17 2022-12-22 Chiesi Farmaceutici S.P.A. Agent for use in treatment or prevention of ophthalmic disorders
IL302317A (en) 2020-10-28 2023-06-01 Dompe Farm Spa Pharmaceutical packaging including polypropylene containers and aqueous formulations of NGF packed in them
EP4039269A1 (en) 2021-02-05 2022-08-10 Dompe' Farmaceutici S.P.A. Ngf isoform for use in the treatment of ocular pathologies
IL307622A (en) 2021-04-13 2023-12-01 Domp? Farm S P A Treatment of neuropathic corneal pain with ngf
EP4311554A1 (en) 2022-07-29 2024-01-31 Dompé farmaceutici S.p.a. Combination for use in ophthalmology
EP4316505A1 (en) 2022-08-05 2024-02-07 Dompé farmaceutici S.p.a. Intranasal administration of ngf for the treatment of sensorineural hearing loss
EP4342485A1 (en) 2022-09-23 2024-03-27 Dompe' Farmaceutici S.P.A. Ngf for the treatment of spasticity
EP4497431A1 (en) 2023-07-27 2025-01-29 Dompé farmaceutici S.p.A. Pharmaceutical formulation comprising nerve growth factor
EP4623927A1 (en) 2024-03-27 2025-10-01 Dompe' Farmaceutici SpA Ngf for use in the prevention or treatment of motor impairment caused by neonatal hypoxic-ischemic encephalopathy
EP4659759A1 (en) 2024-06-04 2025-12-10 Dompé farmaceutici SpA Administration of ngf for the treatment of niemann-pick type c disease

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5169762A (en) * 1983-03-03 1992-12-08 Genentech, Inc. Human nerve growth factor by recombinant technology
US5453363A (en) 1985-10-23 1995-09-26 Boehringer Mannheim Gmbh Process for the activation of t-PA or Ing after genetic expression in prokaryotes
US5683894A (en) 1988-04-29 1997-11-04 University Of California Recombinant nerve growth factor
US5606031A (en) 1990-04-06 1997-02-25 Lile; Jack Production and purification of biologically active recombinant neurotrophic protein in bacteria
US5235043A (en) * 1990-04-06 1993-08-10 Synergen, Inc. Production of biologically active, recombinant members of the ngf/bdnf family of neurotrophic proteins
DE4139000A1 (de) * 1991-11-27 1993-06-03 Boehringer Mannheim Gmbh Verfahren zur gentechnologischen herstellung von biologisch aktivem ss-ngf
DE4405179A1 (de) * 1994-02-18 1995-08-24 Hoechst Ag Verfahren zur Gewinnung von Insulin mit korrekt verbundenen Cystinbrücken
WO1996008562A1 (de) * 1994-09-12 1996-03-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., Berlin Biologisch aktive, von neurotrophinen abgeleitete moleküle
US5935824A (en) * 1996-01-31 1999-08-10 Technologene, Inc. Protein expression system
DE59711375D1 (de) 1996-06-11 2004-04-08 Roche Diagnostics Gmbh Verfahren zur aktivierung von denaturiertem protein
EP0994188B1 (de) 1998-10-09 2004-01-07 Scil proteins GmbH Verfahren zur Gewinnung von aktivem Beta-NGF

Also Published As

Publication number Publication date
JP5275306B2 (ja) 2013-08-28
FR17C0007I2 (fr) 2018-11-09
FR17C0007I1 (fr) 2017-11-17
JP2010280717A (ja) 2010-12-16
US8501439B2 (en) 2013-08-06
US20100203589A1 (en) 2010-08-12
EP0994188A1 (de) 2000-04-19
DE59810555D1 (de) 2004-02-12
AU1034800A (en) 2000-05-01
CA2346257A1 (en) 2000-04-20
KR100593831B1 (ko) 2006-06-28
CA2346257C (en) 2005-03-01
ATE257514T1 (de) 2004-01-15
ES2213861T3 (es) 2004-09-01
BR9914393A (pt) 2001-06-26
JP2002527062A (ja) 2002-08-27
EP0994188B1 (de) 2004-01-07
WO2000022119A1 (de) 2000-04-20
ZA200102780B (en) 2002-07-04
JP4634611B2 (ja) 2011-02-16
KR20010083900A (ko) 2001-09-03
AU765810B2 (en) 2003-10-02
US8318671B1 (en) 2012-11-27
BR9914393B1 (pt) 2021-06-22

Similar Documents

Publication Publication Date Title
NL300894I2 (nl) cenegermin
WO2001044286A3 (en) Five-helix protein
EP1406918B8 (en) The production of soluble keratin derivatives
WO2001075087A3 (en) Subtilisin variants
WO1996017924A3 (en) Novel hedgehog-derived polypeptides
WO2002087411A3 (en) Composite scaffolds and methods using same for generating complex tissue grafts
ES2072918T3 (es) Mejoras en la produccion de polipeptidos.
WO2004090582A3 (en) Method for constructing a catadioptric lens system
WO2004101598A3 (en) Insertion of furin protease cleavage sites in membrane proteins and uses thereof
WO2002006306A3 (en) SUBSTRATES AND ASSAYS FOR β-SECRETASE ACTIVITY
WO2002019520A3 (en) Resonator with preferred oscillation mode
WO2002044203A3 (de) Herstellung von rekombinantem bmp-2
BR0111692A (pt) Processo para preparação de polipeptìdeo il-18 fisiologicamente ativo
WO2002051988A3 (en) Thymic epithelial progenitor cells and uses thereof
ES2168282T3 (es) D-hidantoinasa recombinante, procedimiento para su preparacion y utilizacion.
WO2000005389A3 (en) Production of proteins
WO2004094478A3 (en) Cleavage of fusion proteins using granzyme b protease
NO964861D0 (no) Derivater av aminosulfonsyrer, fremgangsmåte for fremstilling av disse samt deres anvendelse ved syntese av pseudopeptider
EA199900750A1 (ru) Водная фармацевтическая композиция, включающая активный ингредиент, в высшей степени нерастворимый в воде
WO2001014407A3 (de) Rückfaltung von membranproteinen durch verwendung zweifer unterschieldlichen detergentien
BR0213756A (pt) Sistema e método para configurar remotamente um rádio, e, estrutura de dados em um perfil de usuário localizado em um banco de dados
BRPI9913018A (pt) processo para a preparação de somatotropina ativa a partir de corpúsculos de inclusão.
ES2186886T3 (es) Proteinas solubles.
EP0310913A3 (en) Dna isolation procedure
AU4269401A (en) HCV NS2/3 fragments and uses thereof